A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.

Oral Squamous Cell Carcinoma Clinical Trial

— B2023-153  

Official title:

替雷利珠单抗联合含铂双药新辅助治疗用于提高可切除局部晚期口腔鳞癌下颌骨保留的前瞻性、单臂Ⅱ期临床试验

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06130007
• Other study ID #: B2023-153
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 25, 2023
• Est. completion date: October 25, 2024

Study information

• Verified date: November 2023
• Source: Sun Yat-sen University
• Contact: Qi Fang Fang, MD
• Phone: 8613856534831
• Email: fangqi[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Given the feasibility of induction chemotherapy in oral cancer and the encouraging remission rates achieved, we explore the clinical application prospects of using tislelizumab in combination with traditional standard chemotherapy as induction treatment in oral cancer patients who have no radiological evidence of mandibular erosion but require mandibulectomy due to the tumor's proximity to the mandible, aiming to shrink tumor size and increase the rate of mandible preservation. Therefore, we propose to conduct a prospective, single-arm, single-center phase II exploratory clinical trial: we plan to select patients with locally advanced resectable primary oral squamous cell carcinoma T3-4N0-3M0 (stages III-IVb, excluding T1-2) after multidisciplinary consultation and assessment by imaging and clinical evaluation. We aim to explore the feasibility of a three-week treatment regimen combining tislelizumab with polyaletin paclitaxel and a platinum-based triplet, preliminarily assess its clinical efficacy, adverse reactions, and postoperative mandible preservation rate, to provide the best comprehensive treatment plan for the preservation rate of the mandible in oral squamous cell carcinoma.

Description:

In this study, eligible subject will be enrolled into study arm to accept study treatment mandibular Preservation Rate will be the primary outcome measures.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 48
• Est. completion date: October 25, 2024
• Est. primary completion date: September 25, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Inclusion Criteria:

Patients must have a confirmed diagnosis of untreated primary oral squamous cell carcinoma, originating from the buccal mucosa, gums, tongue, or floor of the mouth, with clinical imaging confirming no mandibular invasion. Even in the absence of mandibular invasion, patients must still require mandibular segment resection.

Clinical staging should be T3-4N0-3M0 (Stage III-IVb, excluding T1-2) according to the AJCC 8th edition staging.

Patients must be aged between 18 and 70 years. Performance Status (PS) score should be 0-1. Evaluation by a head and neck oncologist should confirm eligibility for surgical resection.

Patients should have at least one evaluable lesion according to RECIST V1.1 criteria.

Adequate organ function is defined as follows:

Hematology: White blood cells = 4000/µL, neutrophils = 2,000/µL, hemoglobin = 90 g/dL, platelets = 100,000/µL.

Liver function: Bilirubin = 1.5 times the upper limit of normal (ULN) (patients with known Gilbert's disease and serum bilirubin levels = 3 times ULN may be eligible), AST and ALT = 3 times ULN, and alkaline phosphatase = 3 times ULN, with albumin = 3 g/dL.

Renal function: Serum creatinine = 1.5 times ULN or creatinine clearance = 60 mL/min according to the Cockcroft-Gault formula.

Coagulation parameters (APTT and INR) should be = 1.5 × ULN (patients on stable anticoagulation therapy such as low molecular weight heparin or warfarin within the expected therapeutic range may be screened).

Thyroid-stimulating hormone (TSH) should be = ULN. If abnormal, T3 and T4 levels should be assessed, and patients with normal T3 and T4 levels may be eligible.

Patients must have provided informed consent and must be willing and able to adhere to the study plan, visit schedule, treatment plan, laboratory tests, and other study procedures.

Reproductive-age females must agree to use contraceptive measures (e.g., intrauterine device, birth control pills, or condoms) during the treatment period and for three months after treatment completion. A negative serum or urine pregnancy test within 7 days before study entry is required, and patients must not be breastfeeding. Male patients must also agree to use contraceptive measures during the study and for three months after study completion.

Exclusion Criteria:

• Exclusion Criteria:

History of severe hypersensitivity reactions to other monoclonal antibodies or PD-1 monoclonal antibodies or any of their components.

Known or suspected autoimmune diseases, including dementia and epileptic seizures.

Presence of measurable residual disease or new tumor/metastasis according to RECIST1.1 criteria, or patients deemed inoperable following evaluation by a head and neck specialist.

Abnormal coagulation function: (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), a tendency to bleed, or current treatment with thrombolytic or anticoagulant agents.

Severe cardiac or pulmonary dysfunction, with heart or lung function rated below Grade 3 (inclusive).

Abnormal laboratory values within 7 days before enrollment.

History of any of the following treatments:

1. Prior use of anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, or anti-CTLA-4 antibodies (or any other antibodies targeting T cell co-stimulatory or checkpoint pathways).

2. Receipt of any investigational drug within 4 weeks before the first dose of the study drug.

3. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or a follow-up study for a new clinical trial.

4. Pre-existing conditions requiring long-term use of immunosuppressive drugs or the use of corticosteroids at doses with immunosuppressive effects, either systemically or locally.

5. Vaccination with anti-tumor vaccines or receipt of live vaccines within 4 weeks before the first dose of the study drug.

6. Major surgery or severe trauma within 4 weeks before the first dose of the study drug.

Experienced severe infections (CTC AE Grade > 2) within 4 weeks before the first use of the study drug, such as severe pneumonia, septicemia, or complications of infection requiring hospitalization; baseline chest imaging indicating active lung inflammation; presence of symptoms and signs of infection within 2 weeks before the first use of the study drug or the need for oral or intravenous antibiotics (excluding prophylactic antibiotic use).

HIV-positive individuals, those testing positive for HBsAg with concurrent detection of positive HBV DNA copy numbers (quantitative test = 1000 cps/ml); positive screening for chronic hepatitis C (HCV antibody-positive).

History of other malignant tumors in the past 5 years, except for cured basal cell carcinoma, in situ cervical carcinoma, and papillary thyroid carcinoma.

Positive pregnancy test in women of childbearing age and breastfeeding women.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Oral Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Xuekui Liu

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mandibular Preservation Rate;	Mandibular Preservation Rate	12 weeks
Secondary	ORR	Objective Response Rate	12 weeks
Secondary	CR	Complete Response	12 weeks
Secondary	PR	Partial Response	12 weeks
Secondary	SD	Stable Disease	12 weeks
Secondary	PD	Disease Progression	12 weeks
Secondary	MPR	major pathological response	12 weeks
Secondary	pCR	complete pathological response rate	12 weeks
Secondary	PFS	progression-free survival	3 years
Secondary	DFS	disease-free survival	3 years
Secondary	OS	overall survival	3 years
Secondary	AE	Percentage of adverse events that are possibly, probably related to study treatment per Criteria for Adverse Events version 5(CTCAE v5.0)	90 days after the first dose of study treatment